fashion -WSS

fashion

author：fashion 2025-09-06 06:07:02 - browse：82

Immunofluorescence image shows CD4+ (green) and CD8+ (yellow) T cells in the microenvironment of a head and neck squamous cell carcinoma. — This immunofluorescence image shows T cells (in green and yellow) in the microenvironment of a head and neck squamous cell carcinoma. Allen Lab/NCI/NIH

Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62% of patients with head and neck cancer, according to an interim analysis of an ongoing mid-stage clinical trial.

The new efficacy results, derived from a larger number of patients, look similar to an initial disclosure made last week that triggered a 36% increase in Merus’ stock price.

But the Dutch drugmaker on Tuesday withheld additional information from the study related to the safety and durability of petosemtamab’s tumor responses, pending presentation at the annual meeting of the American Society of Clinical Oncology on June 3.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

explore

WSS

National panel will explore requiring free Covid tests

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Weight loss drugs aren’t covered by Obamacare. That may change

MD Anderson's Padmanee Sharma responds to research credit suit

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Mega Millions pot grows to $1.25 billion after no winner

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Moonlake's readout produced a cash windfall. Risks remain

New study raises questions about niacin and heart health

Peter Hotez and the public health issue of online harassment

Surprise medical billing ban raises prices elsewhere

ChatGPT in medicine: STAT answers readers' burning questions

Obamacare plans could cover weight loss drugs

Activists slam private health insurers over coverage restrictions

Measles policy set amid Florida outbreak alarms vaccine proponents

Affirmative action in medical school literally saved lives

Ukraine seeks to reclaim its role as a hub for clinical trials

Wikipedia

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Sage hopes for a blockbuster in antidepressant now before FDA

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Adults seen as increasingly susceptible to measles

Lawsuit alleges UnitedHealth Group unit illegally denied claims

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

explore

entertainment

focus

knowledge